Keyword: Teva Pharmaceutical Industries
The oral CGRP drug ubrogepant met its endpoints in a second phase 3 migraine trial, setting it up for an NDA in 2019.
Eli Lilly presented a post hoc analysis of its monthly migraine therapy galcanezumab, one of a new class of targeted preventive drugs.
The decision, which Alder described as mutual, leaves the biotech without a permanent leader in the runup to filing for approval of its migraine drug.
The Israeli pharma paid $10 million to collaborate with Heptares on CGRP antagonists but has bailed before the first program hit the clinic.
BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.
Novartis Oncology head Bruno Strigini retires, Amneal poaches Allergan's Robert Stewart, plus more hirings, firings and retirings across the industry.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.
Teva's restructuring plan will include the closure or divestiture of R&D facilities, as well as a "thorough review" of its R&D programs.
Teva Pharmaceutical will reveal a restructuring plan on Thursday which includes shutting a research and development center.